AZ has called off new crown vaccine trials and nine other drug companies, including Pfizer, have made commitments.

SEPTEMBER 10 (Xinhua) -- AstraZeneca suspended clinical trials of its new coronavirus vaccine on September 8 after a British volunteer was found to have an unsealable disease, according to media reports.
addition, nine biopharmaceutical companies have pledged not to seek FDA approval before ensuring the safety and effectiveness of vaccines, based on "high ethical standards and sound scientific principles."
the nine companies, including Modelna, Pfizer, AstraZeneta, BioNTech, GlaxoSmithKline, Johnson and Johnson, Merck, Novavax and Sanofi, are trying to reassure the public about the safety and effectiveness of the new crown vaccine.
, Pfizer and AstraZeneta have entered Phase III clinical trials of the new vaccine, out of nine companies that have signed the pledge.
can say that almost all of the multinational pharmaceutical giants with vaccine lines are racing for research and development in the research and development boom that has accompanied the new crown epidemic sweeping the world.
wave, however, has cooled for the first time since the "historic commitment" made by nine companies, or it should be said to be "calm."
the clinical trial was called off, AstraZenecom said it had initiated a standard review process for the ongoing global randomized control group trial of Oxford University's new coronavirus vaccine.
has now "voluntarily suspended vaccinations to ensure that the independent commission checks the safety data of the vaccine."
company is working to expedite verification of this single incident to minimize any potential impact on the research process.
AstraZenecom stressed that "stopping clinical trials is a routine operation to ensure the integrity of the trial and the necessary steps to take when any potential, unseplained disease occurs in a trial."
happens occasionally in large clinical trials, but we have to do a careful independent review of that.
FDA director said in June that in addition to proving the vaccine was safe, pharmaceutical companies would have to prove that the vaccine was 50 percent more effective than a placebo.
in early September, Dr. Slavi, who is leading the U.S. government's production of the new coronavirus vaccine, told NPR, a national public radio station, that the chances of success by October were very low.
The progress of domestic enterprises may be affected on August 6, AstraZeneatic announced the signing of an exclusive authorized cooperation framework agreement with Domestic Kantai Bio in the Chinese mainland market, actively promoting AstraZeneatic's cooperation with Oxford University in the development, production, supply and commercialization of the new crown vaccine AZD1222 in the Chinese mainland market.
, according to Kantai Biocom, the company ensures that it will have sufficient capacity to produce at least 100 million doses per year by 2020 and at least 200 million doses per year by 2021.
, however, Taikang Bio closed down 16.57 per cent after AstraZeneta halted clinical trials.
the concept of another A-share bio-vaccine suffered a heavy setback on the 9th, Taikang Bioseedical Biomedical Company was also affected.
statistics, Zhifei Bio fell 11.91 percent, Wante Bio, Hailey Bio fell, Watson Bio, Hualan Biological fell more than 8 percent.
responded to this by saying that AstraZene is the world's leading research and development company in the new crown vaccine, the largest trial scale, the emergence of individual cases is the normal phenomenon of research and development, does not affect the company's cooperation with AstraZeneta.
the market may have misunderstood the incident.
industry sources noted, however, that the response did not provide further details on the safety events of the vaccine trial, such as which step the adverse reactions occurred in the trial and what adverse reactions were specific to the participants.
according to WHO statistics, as of September 3, there were 34 new crown vaccine products in clinical research and 142 in preclinical stages.
entered Phase III. Clinical products have 8 items, of which China has 3 inactivated vaccines and 1 adenovirus vector vaccine into the global Phase III.
industry has previously revealed that domestic inactivated vaccines can be launched as soon as the end of December.
but whether progress in domestic vaccine research and development will be affected will be the focus of the next step after AstraZeneta shuts down clinical practice.
.